These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Cost-minimization analysis of piperacillin/tazobactam versus imipenem/cilastatin for the treatment of serious infections: a Canadian hospital perspective. Marra FO; Frighetto LO; Marra CA; Sleigh KM; Stiver HG; Bryce EA; Reynolds RP; Jewesson PJ Ann Pharmacother; 1999 Feb; 33(2):156-62. PubMed ID: 10084409 [TBL] [Abstract][Full Text] [Related]
26. Penny and pound wise: pharmacoeconomics from a governmental perspective. van Oostenbruggen MF; Jansen RB; Mur K; Kooijman H Pharmacoeconomics; 2005; 23(3):219-26. PubMed ID: 15836004 [TBL] [Abstract][Full Text] [Related]
27. Pharmacoeconomic comparison of Helicobacter pylori eradication regimens. Sancar M; Izzettin FV; Apikoglu-Rabus S; Besisik F; Tozun N; Dulger G Pharm World Sci; 2006 Aug; 28(4):207-14. PubMed ID: 17066247 [TBL] [Abstract][Full Text] [Related]
28. The use of health economic information by reimbursement authorities. Drummond MF Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii60-3. PubMed ID: 14585919 [TBL] [Abstract][Full Text] [Related]
29. Pharmacy benefit management: enhancing the applicability of pharmacoeconomics for optimal decision making. Mullins CD; Wang J Pharmacoeconomics; 2002; 20(1):9-21. PubMed ID: 11817989 [TBL] [Abstract][Full Text] [Related]
30. Assessing antibacterial pharmacoeconomics in the intensive care unit. Birmingham MC; Hassett JM; Schentag JJ; Paladino JA Pharmacoeconomics; 1997 Dec; 12(6):637-47. PubMed ID: 10175976 [TBL] [Abstract][Full Text] [Related]
31. The role of pharmacoeconomics in disease management. A pharmaceutical benefit management company perspective. Thomas N Pharmacoeconomics; 1996; 9 Suppl 1():9-15. PubMed ID: 10160115 [TBL] [Abstract][Full Text] [Related]
32. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
33. Design, analysis and presentation of multinational economic studies: the need for guidance. Pang F Pharmacoeconomics; 2002; 20(2):75-90. PubMed ID: 11888360 [TBL] [Abstract][Full Text] [Related]
34. [Pharmacoeconomics - Challenges for Health Professionals]. Turčić P; Benković V; Brborović O; Valent A Acta Med Croatica; 2016 Apr; 70(2):117-23. PubMed ID: 28722840 [TBL] [Abstract][Full Text] [Related]
35. Pharmacoeconomic analysis in Saudi Arabia: an overdue agenda item for action. Al-Jazairi AS; Al-Qadheeb NS; Ajlan A Ann Saudi Med; 2011; 31(4):335-41. PubMed ID: 21808106 [TBL] [Abstract][Full Text] [Related]
36. Drug utilisation studies as tools in health economics. Sacristán JA; Soto J Pharmacoeconomics; 1994 Apr; 5(4):299-312. PubMed ID: 10147239 [TBL] [Abstract][Full Text] [Related]
37. [Clinical studies on the pharmacoeconomic expediency of the use of fluoroquinolones]. Mokhov OI Antibiot Khimioter; 1999; 44(7):7-15. PubMed ID: 10494377 [No Abstract] [Full Text] [Related]
38. Pharmacoeconomics and therapeutic drug monitoring. Bootman JL; Harrison DL Pharm World Sci; 1997 Aug; 19(4):178-81. PubMed ID: 9297729 [TBL] [Abstract][Full Text] [Related]